Is QURE a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on AMT-130 accelerated-approval review, with revenue (ttm) at ~$18.7 million (Q2 2026 ~$5.1 million, mostly license and royalty). The bear case rests on uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. Analysts covering it are spread from $28.08 to $91.81, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $28.08, +28.9% from the $21.78 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

AMT-130 accelerated-approval review. The FDA agreed that AMT-130's three-year Phase I/II data could serve as the primary basis for a BLA under the accelerated-approval pathway, and uniQure has now submitted it, before the four-year data were available. The most optimistic analyst target on QURE is $91.81, +321.5% from the $21.78 price. That figure is only reachable if this thesis works close to its best case.

uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. The September 2026 four-year data already showed this: a non-significant 44% cUHDRS slowing at 48 months and serious inflammation-related adverse events in 17% of high-dose patients took about 37% off the stock in a day. The accelerated-approval pathway still requires alignment with the FDA on a confirmatory study, and there is precedent for the agency demanding more evidence in neurology. The rest of the pipeline is early and unproven, so it offers limited support if the lead program falters. As a pre-profit company, uniQure lost about $71 million in Q2 2026 alone, carries about $552 million of debt, and will likely need to raise capital again, which can dilute shareholders, and the stock is highly volatile and prone to large swings around clinical and regulatory news. Competition in Huntington's is also intensifying as rival mechanisms advance. The most pessimistic published target is $28.08, +28.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (AMT-130 accelerated-approval review) stalling in the reported numbers rather than in the narrative, the risk above (uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

uniQure is a clinical-stage biotech that develops one-time AAV gene therapies for serious genetic and central-nervous-system diseases. Its lead program is AMT-130 for Huntington's disease, and it has earlier programs in ALS, epilepsy, and Fabry disease, plus royalties from the approved hemophilia B therapy Hemgenix.

Most of uniQure's value rests on a single asset, AMT-130. As a pre-profit biotech with minimal revenue and large losses, its share price swings sharply on clinical and regulatory news, so outcomes are unusually binary compared with a diversified, cash-flowing company.

AMT-130 is uniQure's investigational one-time gene therapy for Huntington's disease, delivered surgically into the brain. In its Phase I/II study it met the primary endpoint at three years with roughly 75% to 80% slowing of disease progression on cUHDRS versus external controls, but 48-month data released in September 2026 showed about 44% slowing (not statistically significant) on that measure. It holds RMAT, Breakthrough Therapy, and Fast Track designations.